Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/17156
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hockings, Colin | - |
dc.contributor.author | Alsop, Amber E | - |
dc.contributor.author | Fennell, Stephanie C | - |
dc.contributor.author | Lee, Erinna F | - |
dc.contributor.author | Fairlie, W Douglas | - |
dc.contributor.author | Dewson, Grant | - |
dc.contributor.author | Kluck, Ruth M | - |
dc.date | 2018-02-19 | - |
dc.date.accessioned | 2018-02-22T01:09:09Z | - |
dc.date.available | 2018-02-22T01:09:09Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Cell death and differentiation 2018; 25(4): 721-734 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/17156 | - |
dc.description.abstract | The prosurvival Bcl-2 family proteins Mcl-1 and Bcl-xLinhibit apoptosis by sequestering BH3-only proteins such as Bid and Bim (MODE 1) or the effector proteins Bak and Bax (MODE 2). To better understand the contributions of MODE 1 and MODE 2 in blocking cell death, and thus how to bypass resistance to cell death, we examined prescribed mixtures of Bcl-2 family proteins. In a Bim and Bak mixture, Bcl-xLand Mcl-1 each sequestered not only Bim but also Bak as it became activated by Bim. In contrast, in a Bid and Bak mixture, Bcl-xLpreferentially sequestered Bid while Mcl-1 preferentially sequestered Bak. Notably, Bcl-xLcould sequester Bak in response to the BH3 mimetic ABT-737, despite this molecule targeting Bcl-xL. These findings highlight the importance of Bak sequestration in resistance to anti-cancer treatments, including BH3 mimetics. | - |
dc.language.iso | eng | - |
dc.title | Mcl-1 and Bcl-xLsequestration of Bak confers differential resistance to BH3-only proteins. | - |
dc.type | Journal Article | - |
dc.identifier.journaltitle | Cell death and differentiation | - |
dc.identifier.affiliation | The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia | en |
dc.identifier.affiliation | Department of Medical Biology, The University of Melbourne, Parkville, VIC, 3010, Australia | - |
dc.identifier.affiliation | Department of Chemical Engineering and Biotechnology, Cambridge, CB3 0AS, UK | - |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia | - |
dc.identifier.affiliation | School of Cancer Medicine, La Trobe University, Melbourne, VIC, 3086, Australia | - |
dc.identifier.affiliation | Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, Melbourne, VIC, 3086, Australia | - |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/29459767 | - |
dc.identifier.doi | 10.1038/s41418-017-0010-6 | - |
dc.identifier.orcid | 0000-0001-7894-7294 | - |
dc.identifier.orcid | 0000-0002-7101-1925 | - |
dc.identifier.pubmedid | 29459767 | - |
dc.type.austin | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.